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Background and objectives: Chronic obstructive pulmonary disease (COPD) is responsible 
for significant morbidity and mortality worldwide. We evaluated the characteristics of stable 
COPD patients in the pulmonology clinics of seven Asian cities and also evaluated whether 
the exposure to biomass fuels and dusty jobs were related to respiratory symptoms, airflow 
limitation, and quality of life in the COPD patients.
Methods: This cross-sectional observational study recruited 922 COPD patients from seven 
cities of Asia. The patients underwent spirometry and were administered questionnaires about 
their exposure to cigarette smoking, biomass fuels, and dusty jobs in addition to respiratory 
symptoms and health related quality of life.
Results: Of the patients, there appeared to be variations from city to city in the history of 
exposure to biomass fuels and dusty jobs and also in respiratory symptoms of cough, phlegm, 
wheeze, and dyspnea. These symptoms were more frequent in those COPD patients with a 
history of exposure to biomass fuels than without and those with a history of exposure to dusty 
jobs than without (P , 0.01 for all comparisons). Airflow limitation was more severe in those 
COPD patients with a history of exposure to biomass fuels than without (52.2% predicted versus 
55.9% of post-bronchodilator forced expiratory volume in 1 second [FEV1], P = 0.009); quality 
of life was poorer in those with exposure to biomass fuels than without (40.4 versus 36.2 of 
the St George’s Respiratory Questionnaire [SGRQ] total score, P = 0.001). Airflow limitation 
was more severe in those COPD patients with a history of exposure to dusty jobs than without 
(51.2% predicted versus 57.3% of post-bronchodilator FEV1, P , 0.001); quality of life was 
poorer in those with dusty jobs than without (41.0 versus 34.6 of SGRQ score, P = 0.006).
Conclusion: In Asian cities, the characteristics of COPD patients vary and the history of 
exposure to biomass fuels or dusty jobs was related to frequency of symptoms, severe airflow 
limitation, and poor quality of life.
Keywords: COPD, Asia, biomass, dust
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide.1 
Its high prevalence and associated medical expenses impose large socioeconomic 
burdens.
This is especially true in Asian cities, due to high rates of smoking, outdoor or 
indoor air pollution including biomass fuel combustion, and exposure to occupational 
dusts and noxious gases.2,3 COPD shows heterogeneous features that are demonstrated 
with the variability in symptoms, comorbidities, and exacerbations.4,5 The heteroge-
neity of COPD may be due to the variations in genetic influences and environmental 
exposures among which exposures to biomass fuels and dusty jobs were reported to be 
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related with the development of COPD in Asia.6,7 Therefore, 
to assess the heterogeneity of COPD, it would be reasonable 
to compare the exposure history of biomass fuels and dusty 
jobs, demographic characteristics, and clinical characteristics 
of COPD patients from different cities or regions.
The Asian Network for Obstructive Lung Disease 
(ANOLD)8 is a group of collaborative researchers studying 
the heterogeneous characteristics of Asian COPD patients. 
We have evaluated the history of exposure to biomass fuels 
and dusty jobs, respiratory symptoms, health-related quality 
of life, comorbidities, and respiratory medications in COPD 
patients from seven cities in Asia. We also examined the 
relations of respiratory symptoms, severe airflow limitation, 
and poor quality of life to the exposure to biomass fuels and 
dusty jobs. We hypothesized that biomass fuel exposure or 
dusty job exposure would be related to increased risks of 
respiratory symptoms, severe airflow limitation, and poor 
quality of life in COPD patients.
Methods
Study design
This was a cross-sectional observational study involving 
COPD patients from seven Asian cities. Patients underwent 
simple chest radiography and pre- and post-bronchodilator 
spirometry and were administered questionnaires about 
respiratory symptoms; exposure to tobacco smoking, bio-
mass fuels, and dusty jobs; health-related quality of life; 
comorbidities; and respiratory medication during a single 
visit. This study was approved by the Institutional Review 
Board at every participating center, and all study participants 
provided written informed consent.
Study subjects
COPD patients were recruited between September 2009 and 
September 2010 at the pulmonary clinics in seven Asian 
  cities: Beijing, China; Colombo, Sri Lanka; Penang,   Malaysia; 
Quezon City, Philippines; Sapporo, Japan; Seoul, Korea; and 
Taipei, Taiwan. The Japanese data were obtained from the 
Hokkaido COPD study;9 the Korean data were obtained from 
a Korean cohort of obstructive lung disease named the KOLD 
cohort.10 Ten clinics or hospitals in or near Sapporo, eleven in 
or near Seoul, and only one in other Asian cities participated 
in the recruitment of patients. The above seven cities were 
chosen as they were the location of the authors’ study group, 
the Asian Network for Obstructive Lung Disease.
All COPD patients were of Asian ethnicity, 
aged $40 years and had post-salbutamol forced expiratory 
volume in 1 second/forced vital capacity (FEV1/FVC) 
ratio , 0.7. Smokers were defined as individuals with a 
history of cigarette smoking for at least 10 pack-years, 
whereas nonsmokers were defined as individuals with a 
lifetime history of ,100 cigarettes.
Patients were excluded if they had a history of asthma, 
bronchiectasis, tuberculosis, or other concomitant respira-
tory diseases. Patients with old healed tuberculosis with 
sequelae not associated with cavities or destroyed lung, 
but associated both with the extent of radiological lesion 
not extending beyond one lobe territory and with the above 
defining criteria of COPD were included. Patients were also 
excluded if they were in an exacerbated state but they were 
allowed to participate one month after an exacerbation. 
Patients were also excluded if they had a history of prior 
lung surgery including lung volume reduction, uncontrolled 
cancer, or radiation therapy to the chest, mediastinum, or 
breast. Patients who refused salbutamol administration and 
pregnant women were excluded.
Questionnaires
The standardized questionnaires assessed respiratory history 
and symptoms, smoking history, family history, health-
related quality of life, comorbidities, and current respiratory 
medications. These questionnaires included a modified 
version of the American Thoracic Society Division of Lung 
Diseases Respiratory Epidemiology Questionnaire, Charlson 
comorbidity conditions and the St George’s Respiratory 
Questionnaire (SGRQ). Questionnaires were administered 
by interviewers.11–13
Cigarette smoking was evaluated using the question, 
“Have you ever smoked cigarettes? (No means less than 100 
cigarettes in your life).” Biomass fuel exposure was evaluated 
using the question, “For cooking and/or heating, have you 
ever been exposed to biomass fuels such as wood, agricultural 
crop residues, animal dung, charcoal, and others?” Exposure 
to a dusty job was evaluated using the question, “Have you 
ever worked for 1 year or more at any dusty job?” Paternal 
(or maternal) smoking was evaluated with the question, “Was 
your father (or mother) ever a cigarette smoker?”
Cough was evaluated using the question, “Do you usually 
have a cough? (excluding clearing of the throat),” and phlegm 
was evaluated with the question, “Do you usually bring up 
phlegm from your chest?” Chronic bronchitis was defined 
as both cough and phlegm for over 3 consecutive months 
for a period of more than 2 years.14 Wheeze was evaluated 
with the question, “Have you ever had wheezing or whistling 
in your chest?” Dyspnea was evaluated using the modified 
Medical Research Council Dyspnea grade.15
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Current medications were evaluated using the question, 
“At present, do you use medications to treat your breathing 
problems?” If the subject answered yes, he or she was asked 
to choose specific medication(s).
Spirometry and body mass index
Spirometry was performed as proposed by the American 
Thoracic Society/European Respiratory Society (ATS/
ERS) Task Force.16 For post-bronchodilator spirometry we 
used 200 µg of salbutamol with a spacer. We used various 
spirometric machines (Chestac; Chest MI Inc, Tokyo, Japan; 
MasterScreen pulmonary function test [PFT]; CareFusion 
Corporation, San Diego, CA; Vmax Encore 22; CareFusion 
Corporation; KoKo Spirometry; Pulmonary Data Services Inc, 
Louisville, CO; Quark PFT 4; Cosmed, Rome, Italy), each of 
which was calibrated daily. Quality control of spirometry was 
performed at the center of each city and also monitored at the 
Coordination Center at Asan Medical Center, Seoul, Korea. At 
each center the same personnel performed spirometry using 
the same spirometry machine which was calibrated daily 
with syringe. The graphs of spirometry were delivered to and 
monitored by the Coordination Center. The reference equa-
tions for spirometry were developed from corresponding local 
populations for Japan and Korea, or adopted from European 
populations for the other countries.17–20
Body mass index (BMI) was calculated as the patient’s 
weight in kilograms divided by the square of the height in 
meters. Underweight was defined as BMI , 18.5 kg/m2 and 
overweight as BMI $ 25 kg/m2.21
Data analysis
The Chi-square or Kruskal–Wallis test was performed for the 
evaluation of variation in patients’ characteristics among the 
seven Asian cities. Multiple logistic regression analysis was 
performed to evaluate whether the risk factor of biomass fuel (or 
dusty job) exposure was associated with respiratory symptoms 
after the adjustment for age, sex, Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage, cigarette smoking, 
exposure to dusty jobs (or biomass fuels), and city.
P-values ,0.05 were considered statistically significant. 
All statistical analyses were performed with SPSS version 
18.0 software (IBM Corporation, Armonk, NY).
Results
Characteristics of subjects
Between September 2009 and September 2010, we recruited 
922 COPD patients from pulmonology clinics of seven cities in 
Asia: 70 in Beijing, China; 268 in Sapporo, Japan; 173 in Seoul, 
Korea; 92 in Penang, Malaysia; 109 in Quezon City, Philippines; 
110 in Colombo, Sri Lanka; and 100 in Taipei, Taiwan.
We observed a variation of characteristics of the patients 
with COPD collected from the seven Asian cities in terms of 
possible exogenous causes, lung function, clinical symptoms 
(dyspnea score, presence of chronic bronchitis), health-
related quality of life, comorbidities, and history of lung 
problems including exacerbations (Figure 1 and Table 1; 
P value ,0.001 for all analyses).
Table 1 shows the demographic and clinical character-
istics of the 922 patients by city. Overall mean age was 68.2 
years (standard deviation 8.5 years) and 864 of the subjects 
(93.7%) were male. We found that 296 patients (32.1%) had 
a history of exposure to biomass fuels and 412 (44.7%) had 
an occupational history of dusty jobs.
The prevalence of biomass exposure differed from city 
to city throughout Asia, ranging from 0% in Sapporo, Japan, 
to 97.2% in Quezon City, Philippines. Biomasses included 
wood (85.0%), charcoal (8.7%), and agricultural crop 
residues (4.2%). Of the 922 COPD patients, 201 (21.8%) 
had symptoms of chronic bronchitis and 693 (75.2%) 
had wheeze. Mean BMI was 22.1 kg/m2, mean predicted 
post-bronchodilator FEV1 was 54.7% and mean total SGRQ 
score was 37.5. The proportion of COPD patients with under-
weight and overweight were 19.4% and 20.5%, respectively.
Of the COPD patients, 43 (4.7%) had no history of 
cigarette smoking and 879 (95.3%) were cigarette smokers. 
Among them 222 (24.1%) were current cigarette smokers 
and 657 (71.3%) were past smokers (Table 2). We found 
that 63.9% of these patients had fathers who smoked and 
that 16.7% had mothers who smoked.
Comorbidities and current respiratory medications
We found that 8.8% and 8.5% of the COPD patients had a 
history of diabetes mellitus and ulcer disease, respectively, 
and that 3.6% and 3.5% had a history of myocardial infarc-
tion and cerebrovascular disease, respectively.
Of the COPD patients, 81.8% reported that they were cur-
rently using medications to treat breathing problems. Of these 
patients, 38.7% were using theophylline, 37.6% an inhaled 
long-acting muscarinic antagonist, 35.1% an inhaler contain-
ing a combination of a corticosteroid and a long-acting beta-
agonist, and 32.0% an inhaled short-acting beta-agonist.
Respiratory symptoms and exposure  
to biomass fuels or dusty jobs
Respiratory symptoms, including cough, phlegm, wheeze, and 
dyspnea, were more frequent in those COPD patients with a 
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history of exposure to biomass fuels than without and in those 
with a history of exposure to dusty jobs than without (Table 3). 
For some of the symptoms, these relationships remained 
even after the adjustment for age, sex, GOLD stage, cigarette 
smoking, biomass fuel exposure, dusty job exposure, and city 
(Table 4). Multivariable analysis showed that, for biomass fuel 
exposure, the odds ratios (ORs) of cough, phlegm, wheeze, and 
dyspnea were 1.11 (95% confidence interval [CI]: 0.72–1.72), 
1.39 (95% CI: 0.85–2.26), 1.37 (95% CI: 0.82–2.27), and 1.08 
(95% CI: 0.70–1.66), respectively, and, for dusty job exposure, 
the ORs of these symptoms were 1.47 (95% CI: 1.01–2.14), 
1.77 (95% CI: 1.16–2.69), 1.51 (95% CI: 0.98–2.35), and 1.19 
(95% CI: 0.81–1.77), respectively.
Airflow limitation and exposure  
to biomass fuels or dusty jobs
Airflow limitation appeared to be more severe in the COPD 
subjects with a history of exposure to biomass fuels or dusty 
100
Cigarette smoker (%)
80
60
40
20
0
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
Subjects exposed to biomass
fuel (%)
Subjects exposed to dusty
job (%)
100
80
60
40
20
0
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
100
80
60
40
20
0
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
100
% of subjects according to
dyspnea score
Post-BD FEV1 (% predicted)
80
60
40
20
0
4
3
2
1
0
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
Subjects with chronic
bronchitis (%)
Subjects with history of ER
visit or hospitalization due 
to lung problem (%) 100
80
60
40
20
0
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
100
80
60
40
20
0
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
200
100
50
0
SGRQ total score
B
e
j
i
n
g
S
a
p
p
o
r
o
S
e
o
u
l
P
e
n
a
n
g
Q
u
e
z
o
n
C
o
l
o
m
b
o
T
a
i
p
e
i
60
50
40
30
20
10
Figure 1 Characteristics of subjects according to Asian cities.
Abbreviations: BD, bronchodilator; FEV1, forced expiratory volume in 1 second; SGRQ, St George’s Respiratory Questionnaire.
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Table 1 Characteristics of subjects in seven Asian countries
Total Beijing, 
China
Sapporo, 
Japan
Seoul, 
Korea
Penang, 
Malaysia
Quezon, 
Philippines
Colombo, 
Sri Lanka
Taipei, 
Taiwan
Subjects, number 922* (100%) 70 268 173 92 109 110 100
Mean age, years (SD) 68.2 (8.5) 68.9 (7.1) 69.4 (8.1) 69.0 (7.4) 68.3 (8.8) 64.1 (8.8) 63.8 (8.1) 72.3 (8.4)
Male 864 (93.7%) 69 (98.6%) 252 (94.0%) 164 (94.8%) 83 (90.2%) 100 (91.7%) 103 (93.6%) 93 (93.0%)
Cigarette smoker 879 (95.3%) 68 (97.1%) 267 (99.6%) 170 (98.3%) 92 (100%) 100 (91.7%) 89 (80.9%) 93 (93.0%)
Biomass exposure 296 (32.1%) 41 (58.6%) 0 (0%) 89 (51.4%) 13 (14.1%) 106 (97.2%) 34 (30.9%) 13 (13.0%)
Dusty job 412 (44.7%) 31 (44.3%) 63 (23.5%) 80 (46.2%) 42 (45.7%) 94 (86.2%) 58 (52.7%) 44 (44.0%)
Cough 457 (49.6%) 32 (45.7%) 46 (17.2%) 103 (59.5%) 60 (65.2%) 90 (82.6%) 98 (89.1%) 28 (28.0%)
Phlegm 540 (58.6%) 51 (72.9%) 68 (25.4%) 142 (82.1%) 82 (89.1%) 92 (84.4%) 77 (70.0%) 28 (28.0%)
Chronic bronchitis 201 (21.8%) 16 (22.9%) 28 (10.4%) 59 (34.3%) 18 (19.6%) 30 (27.5%) 29 (26.4%) 21 (21.0%)
Wheeze 693 (75.2%) 63 (90.0%) 171 (63.8%) 112 (64.7%) 74 (80.4%) 96 (88.1%) 102 (92.7%) 75 (75.0%)
MMRC dyspnea
  Grade 0 118 (12.8%) 16 (22.9%) 44 (16.4%) 31 (17.9%) 7 (7.6%) 0 (0%) 5 (4.5%) 15 (15.2%)
  Grade 1 197 (21.4%) 14 (20.0%) 78 (29.1%) 54 (31.2%) 18 (19.6%) 0 (0%) 18 (16.4%) 15 (15.2%)
  Grade 2 299 (32.4%) 27 (38.6%) 138 (51.5%) 48 (27.7%) 7 (7.6%) 0 (0%) 47 (42.7%) 32 (32.3%)
  Grade 3 243 (26.4%) 6 (8.6%) 6 (2.2%) 26 (15.0%) 50 (54.3%) 107 (98.2%) 25 (22.7%) 23 (23.2%)
  Grade 4 64 (6.9%) 7 (10.0%) 2 (0.7%) 14 (8.1%) 10 (10.9%) 2 (1.8%) 15 (13.6%) 14 (14.1%)
Body mass index, kg/m2 (SD) 22.1 (4.2) 24.0 (3.9) 22.3 (3.2) 23.0 (3.3) 21.1 (3.7) 20.8 (5.6) 20.0 (4.0) 23.8 (5.0)
Underweight 179 (19.4%) 7 (10.1%) 37 (13.8%) 17 (9.8%) 23 (25.0%) 35 (32.1%) 52 (47.3%) 8 (8.0%)
Overweight 189 (20.5%) 30 (42.9%) 49 (18.3%) 42 (24.3%) 13 (14.1%) 12 (11.0%) 11 (9.1%) 32 (32.0%)
Post-bronchodilator 
FEV1, liters (SD)
1.38 (0.61) 1.25 (0.36) 1.72 (0.67) 1.64 (0.56) 1.01 (0.41) 1.09 (0.47) 1.12 (0.35) 1.03 (0.45)
Post-bronchodilator 
FEV1, % predicted (SD)
54.7% (20.0) 47.2% (14.1) 63.4% (21.2) 56.4% (17.2) 47.3% (18.7) 50.2% (19.5) 52.3% (16.6) 47.9% (21.0)
GOLD
  Stage Ι† 115 (12.5%) 1 (1.4%) 62 (23.1%) 16 (9.2%) 7 (7.6%) 12 (11.0%) 9 (8.2%) 8 (8.1%)
  Stage II† 392 (42.5%) 29 (41.4%) 126 (47.0%) 92 (53.2%) 30 (32.6%) 39 (35.8%) 46 (40.0%) 30 (30.0%)
  Stage III† 324 (35.1%) 32 (45.7%) 67 (25.0%) 55 (31.8%) 40 (43.5%) 43 (39.4%) 46 (43.6%) 41 (41.4%)
  Stage IV† 86 (9.3%) 8 (11.4%) 13 (4.9%) 10 (5.8%) 15 (16.3%) 15 (13.8%) 9 (8.2%) 16 (16.2%)
SGRQ
  Symptoms score 50.5 41.3 53.5 45.4 55.1 51.0 62.0 40.2
  Activity score 50.4 37.5 44.0 49.0 60.3 67.9 56 44.2
  Impact score 26.1 22.1 22.8 23.3 26.9 35.2 35.8 20.9
  Total score (SD) 37.5 (18.6) 29.8 (16.0) 34.5 (16.7) 34.8 (18.0) 41.5 (20.3) 47.8 (15.0) 46.1 (19.5) 31.2 (19.2)
Notes: *Number of subjects with percentages in parentheses, if not specified otherwise. Underweight = body mass index , 18.5 kg/m2; overweight $ 25 kg/m2. The Chi-
square or Kruskal–Wallis test was performed for the evaluation of variation in the above characteristics among the seven Asian cities (Beijing, China; Colombo, Sri Lanka; 
Penang, Malaysia; Quezon City, Philippines; Sapporo, Japan; Seoul, Korea; and Taipei, Taiwan) (P , 0.001 for all comparisons among the cities).
Abbreviations: SD, standard deviation; MMRC, modified Medical Research Council; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; SGRQ, St George’s Respiratory Questionnaire.
jobs than without (Table 3). The mean of post-bronchodilator 
FEV1 was 52.2% of predicted value versus 55.9% for the 
COPD subjects with versus without biomass exposure; 51.2% 
of predicted value versus 57.3% for the subjects with versus 
without dusty job exposure (both comparisons, P , 0.01).
Health-related quality of life and exposure 
to biomass fuels or dusty jobs
Quality of life appeared to be poorer in the COPD subjects 
with a history of exposure to biomass fuels or dusty jobs than 
without (Table 3). The mean of the total SGRQ score was 
40.4 versus 36.2 for the COPD subjects with versus with-
out biomass exposure (P = 0.001); 41.0 versus 34.6 for the 
subjects with versus without dusty job exposure (P = 0.006). 
Multivariable analysis showed that being female or in a 
higher GOLD stage was related to poor quality of life. The 
OR of male to female was 0.48 (95% CI: 0.25–0.91) for poor 
quality of life. The ORs of GOLD stage II, III, and IV to 
GOLD I were 1.8 (95% CI: 1.1–2.8), 4.4 (95% CI: 2.8–7.0), 
and 12.0 (95% CI: 6.0–24.0), respectively.
Discussion
We have shown here that there were variations of COPD 
patients from seven Asian cities in the exposure history 
to biomass fuels and dusty jobs and also in respiratory 
  symptoms. The symptoms were more frequent, airflow limi-
tation was more severe, and quality of life was poorer in those 
COPD patients with a history of exposure to biomass fuels 
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Table 2 Cigarette smoking history
Total Beijing, 
China
Sapporo, 
Japan
Seoul, 
Korea
Penang, 
Malaysia
Quezon, 
Philippines
Colombo, 
Sri Lanka
Taipei, 
Taiwan
P-value
Current smoker 222* (24.1%) 14 (20.0%) 72 (26.9%) 53 (30.6%) 30 (32.6%) 11 (10.1%) 20 (18.2%) 22 (22.0%) ,0.001
Past smoker 657 (71.3%) 54 (77.1%) 195 (72.8%) 117 (67.6%) 62 (67.3%) 89 (81.7%) 69 (62.7%) 71 (71.0%) ,0.001
Never smoker 43 (4.7%) 2 (2.9%) 1 (0.4%) 3 (1.7%) 0 (0%) 9 (8.3%) 21 (19.1%) 7 (7.0%) ,0.001
Smoking amount† 
(pack-years)
50.3 55.5 76.8 45.9 64.4 40.1 22.6 57.1 ,0.001
Paternal smoking  
history
418 (63.9%) 48 (68.6%) n/a 116 (67.1%) 56 (60.9%) 74 (67.9%) 53 (48.2%) 71 (71.0%) ,0.001
Maternal  
smoking history
109 (16.7%) 20 (28.6%) n/a 36 (20.8%) 12 (13.0%) 33 (30.3%) 1 (0.9%) 7 (7.0%) ,0.001
Notes: *Numbers of subjects with percentages in parentheses; †mean amount of cigarette smoking calculated only among current or past smokers. P-values were obtained 
by Chi-square test.
Abbreviation: n/a, not available.
Table 3 Comparison of subjects who were exposed to biomass fuels or a dusty job with nonexposed subjects
Biomass exposure Dusty job
296 subjects  
answered “yes”
626 subjects  
answered “no”
P-value 412 subjects  
answered “yes”
496 subjects  
answered “no”
P-value
Sex 0.032 0.003
  Male 270* (91.2%) 594 (94.9%) 395 (95.9%) 457 (92.1%)
  Female 26 (8.8%) 32 (5.1%) 17 (4.1%) 39 (7.9%)
Cigarette Smoking
  Current smoker 58 (19.6%) 164 (26.2%) ,0.001 91 (22.1%) 126 (25.4%) 0.313
  Past smoker 209 (70.6%) 444 (70.9%) 299 (72.6%) 346 (69.8%)
  Never smoker 29 (9.8%) 18 (2.9%) 22 (5.3%) 24 (4.8%)
    Smoking amount† 
(pack-years)
46.1 52.9 0.018 47.2 52.5 0.195
Cough 202 (68.2%) 255 (40.7%) ,0.001 256 (62.1%) 200 (40.3%) ,0.001
Phlegm 237 (80.1%) 303 (48.4%) ,0.001 290 (70.4%) 247 (49.8%) ,0.001
Chronic bronchitis 99 (33.4%) 137 (21.9%) ,0.001 127 (30.8%) 108 (21.8%) 0.001
Wheeze 245 (82.8%) 448 (71.6%) ,0.001 330 (80.1%) 358 (72.2%) 0.003
Dyspnea, MMRC  
dyspnea grade
,0.001
 0 25 (8.5%) 93 (14.9%) 36 (8.7%) 80 (16.1%) ,0.001
 1 49 (16.6%) 147 (23.5%) 70 (17.0%) 121 (24.4%)
 2 64 (21.6%) 236 (37.7%) 118 (28.6%) 178 (35.9%)
 3 137 (46.3%) 106 (16.9%) 159 (38.6%) 82 (16.5%)
 4 21 (7.1%) 43 (6.9%) 28 (6.8%) 35 (7.1%)
Post-bronchodilator 
FEV1, % predicted†
52.2% predicted 55.9% predicted 0.009 51.2% predicted 57.3% predicted ,0.001
Total score of SGRQ† 40.4 36.2 0.001 41.0 34.6 0.006
Notes: *Numbers of subjects with percentages in parentheses, if not specified; †mean values.
Abbreviations: MMRC, Modified Medical Research Council; FEV1, forced expiratory volume in 1 second; SGRQ, St George’s Respiratory Questionnaire.
than without and those with a history of exposure to dusty 
jobs than without. Our findings suggest that both biomass 
fuel exposure and dusty job exposure might contribute to 
COPD morbidity in Asian cities.
In this study symptoms of COPD, cough, phlegm, wheeze, 
and dyspnea were more frequent in the COPD patients with 
a history of exposure to biomass fuels or dusty jobs than 
without. Among the symptoms, cough and phlegm were 
more frequent in COPD patients with exposure to dusty jobs 
even after the adjustment for age, sex, GOLD stage, cigarette 
smoking, exposure to biomass fuels, and city. These findings 
suggest that exposure to dusty jobs might impose bronchitis 
symptoms in the COPD patients, most of whom were past 
or current cigarette smokers in this study.
We found that the proportion of COPD subjects exposed 
to biomass fuels differed from city to city in Asia, with 
a range from 0% to 97.2%. Biomass exposure in women 
(44.8% = 100 × 26/58) was higher than that in men 
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(31.3% = 100 × 270/864) (Table 3). This might be related to 
women’s cooking and heating with biomass fuels. Although 
men’s exposure to biomass fuels appeared to be less than 
women’s, men’s exposure percentage of 31% was also 
considerable, which suggests that biomass fuel exposure 
may be important for men as well as for women. Exposure 
to biomass fuels has been reported to be an important risk 
factor for the development of COPD in both Asian and non-
Asian cities.22,23 Similar to previous findings, we found that 
32.1% of our COPD subjects had been exposed to biomass 
combustion,24 and that this exposure may be related to respi-
ratory symptoms. This finding is in agreement with a report 
showing the development of respiratory symptoms in Indians 
using domestic cooking fuels.23 In Sapporo, no patient had an 
exposure history of biomass fuels. They did not use biomass 
fuels at all as energy resources because oil and/or gas supply 
by the local government or by private companies were almost 
perfect in all areas throughout Japan including Sapporo.
Exposure to dusty jobs has been reported to be a risk 
factor for the development of COPD.24 In addition to having 
a role in the development of COPD, these jobs were associ-
ated with an increase in respiratory symptoms in patients 
with COPD in our study. Our findings therefore emphasize 
the importance of asking for history about exposure to dusty 
jobs, as well as cigarette smoking and biomass fuels, when 
examining COPD patients in Asia.
Of our COPD subjects, 8.8%, 8.5%, 3.6%, 4.3%, and 3.5% 
had histories of diabetes mellitus, ulcer disease, myocardial 
infarction, peripheral vascular disease, and cerebrovascular 
disease, respectively. The prevalence of diabetes mellitus in the 
general populations of Asia-Pacific regions has been reported 
to range from 3.7% to 13.3%.25 In addition, the prevalence 
of diabetes mellitus may not differ between individuals with 
and without COPD. For example, the prevalence of diabetes 
mellitus in individuals in Saskatchewan, Canada, with and 
without COPD has been reported to be 14.5% and 12.4%, 
respectively.26 The prevalence of ulcer disease in our study was 
comparable to the 8.5% previously reported,27 and the preva-
lence of myocardial infarction and cerebrovascular disease in 
our study was comparable to previous findings.26,28 We found 
that 38.7%, 35.1%, 32.0%, and 37.6% of our COPD patients 
were taking theophylline, an inhaler containing a combination 
of a corticosteroid and a long-acting beta-agonist, an inhaled 
short-acting beta-agonist, or an inhaled long-acting muscar-
inic antagonist, respectively. The usage of each medication 
appeared to differ from city to city. The various combina-
tions of these treatments may differ within Asian countries 
and also differ to those used in Western countries. Theophyl-
line was the most prevalent and appears to be higher than in 
Western countries,29 perhaps due to its relatively low cost.
Limitations
The COPD patients were recruited not with random or 
systematic sampling but with convenient sampling, which 
inherently has a potential limitation of selection bias. Thus, 
the data in this manuscript may not accurately represent the 
cities of Asian countries. Despite the potential limitation of 
selection bias, this study provides a meaningful profile of 
COPD patients’ characteristics in seven Asian cities.
Secondly, the percentage of females was low in our study, 
perhaps due to the relatively low percentage of Asian females 
who smoke cigarettes.2 Besides the low percentage of ciga-
rette smokers in females of these countries, there might be 
other possibilities why the female COPD subjects were very 
Table 4 Odds ratios of risk factors for respiratory symptoms
Cough Phlegm Chronic bronchitis Wheeze Dyspnea
Age, years 1.00 (0.98–1.02)* 1.01 (0.98–1.03) 1.01 (0.98–1.03) 0.98 (0.95–1.01) 1.02 (1.00–1.05)
Male 1.78 (0.83–3.85) 1.04 (0.42–2.59) 0.77 (0.34–1.73) 0.63 (0.22–1.75) 0.41 (0.16–1.10)
GOLD
  Stage II† 1.05 (0.54–2.05) 1.31 (0.65–2.62) 1.10 (0.53–2.27) 0.80 (0.39–1.65) 1.49 (0.74–2.99)
  Stage III† 1.43 (0.72–2.83) 2.02 (0.98–4.14) 1.51 (0.73–3.12) 1.41 (0.67–2.98) 3.83 (1.86–7.87)‡
  Stage IV† 1.40 (0.61–3.21) 3.49 (1.36–8.97)‡ 2.36 (1.01–5.49)‡ 6.61 (1.71–25.51)‡ 10.99 (3.68–32.79)‡
Biomass exposure 1.11 (0.72–1.72) 1.39 (0.85–2.26) 1.12 (0.72–1.74) 1.37 (0.82–2.27) 1.08 (0.70–1.66)
Dusty job 1.47 (1.01–2.14)‡ 1.77 (1.16–2.69)‡ 1.59 (1.07–2.34)‡ 1.51 (0.98–2.35) 1.19 (0.81–1.77)
Cigarette smoking
  Past§ 1.31 (0.56–3.03) 1.45 (0.65–3.23) 1.27 (0.54–2.98) 1.25 (0.46–3.37) 2.14 (0.89–5.16)
  Current§ 2.36 (0.95–5.84) 2.13 (0.87–5.20) 2.43 (0.98–5.99) 1.22 (0.42–3.50) 1.67 (0.66–4.22)
Notes: *Odds ratios with 95% confidence intervals in parentheses were presented by multiple logistic regression analysis after adjustment for age, sex, GOLD stage of 
COPD, smoking, and also city; †reference was GOLD stage I; ‡statistically significant relationship with P , 0.05; §reference was never smoker. The outcome (dependent) 
variables were binary variables of cough, phlegm, chronic bronchitis (combined symptoms of cough and phlegm), wheeze, and dyspnea. Dependent variables were age, sex, 
COPD severity of GOLD stage, history of exposure to biomass fuels, exposure to dusty jobs, cigarette smoking, and city.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease.
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low in percentage. It would be less likely that Asian women 
may be referred to subspecialty clinics for COPD because 
biomass exposure is relatively unknown as a risk factor and 
also less likely that Asian women will consent to participate 
in clinical studies. Another possibility would be that health 
care might be less accessible for Asian women. Because this 
study is a clinic-based cross-sectional study, there seem to 
be several sorts of selection biases that might influence the 
characteristics of COPD patients. Future population-based 
studies could reveal the reasons why the percentage of women 
COPD patients was so low in Asian referral clinics.
Thirdly, the questions for biomass fuel exposure and dusty 
job exposure have not been validated yet. Further study with 
a validated questionnaire is needed to confirm our findings. 
On the contrary, the questions of cough, phlegm, and wheeze 
were adopted from the American Thoracic Society Division 
of Lung Diseases Respiratory Epidemiology Questionnaire 
that was validated as were the Charlson comorbidity condi-
tions and the SGRQ.11–13
Finally, it is difficult to draw a definite conclusion with this 
study of a cross-sectional design. A follow-up study is needed 
to draw a confirmative conclusion from our findings.
Despite these possible limitations, our study showed 
that the characteristics of Asian COPD patients might differ 
from city to city in Asia, and might also differ from those of 
Western COPD patients.
Conclusion
The characteristics of COPD patients in Asian cities are 
various and a history of exposure to biomass fuels or dusty 
jobs was related to more frequent symptoms, severe airflow 
limitation, and poor quality of life.
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